Precious Metals

[gfp927z]

ALPS Medical Breakthroughs ETF (SBIO)

Performance over 1-Year: 20.9%
Expense Ratio: 0.50%
Annual Dividend Yield: 0.04%
3-Month Average Daily Volume: 66,070
Assets Under Management: $188.3 million
Inception Date: December 30, 2014
Issuing Company: ALPS

SBIO is a fund focused on the U.S. health and biotechnology sector, targeting companies with drugs in Phase II or Phase III clinical trials. This fund invests in firms with market caps of $200 million to $5 billion, so it contains micro-cap and mid-cap companies, as well as small-cap, in its portfolio.6? The fund's top three holdings include Immunomedics Inc. (IMMU), a pharmaceuticals company focused on cancer treatments; United Therapeutics Corp. (UTHR), a biotechnology company; and Acceleron Pharma Inc. (XLRN), a biopharmaceutical company

<<<

https://www.investopedia.com/investing/small-cap-etfs/?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral&yptr=yahoo